Diagnosis and Treatment Trends in Mucopolysaccharidosis I: Findings from the MPS I Registry

DSpace/Manakin Repository

Diagnosis and Treatment Trends in Mucopolysaccharidosis I: Findings from the MPS I Registry

Citable link to this page


Title: Diagnosis and Treatment Trends in Mucopolysaccharidosis I: Findings from the MPS I Registry
Author: D’Aco, Kristin; Underhill, Lisa; Rangachari, Lakshmi; Arn, Pamela; Giugliani, Roberto; Okuyama, Torayuki; Wijburg, Frits; Kaplan, Paige; Cox, Gerald Frank

Note: Order does not necessarily reflect citation order of authors.

Citation: D’Aco, Kristin, Lisa Underhill, Lakshmi Rangachari, Pamela Arn, Gerald F. Cox, Roberto Giugliani, Torayuki Okuyama, Frits Wijburg, and Paige Kaplan. 2012. Diagnosis and treatment trends in mucopolysaccharidosis I: Findings from the MPS I registry. European Journal of Pediatrics 171(6): 911-919.
Full Text & Related Files:
Abstract: Our objective was to assess how the diagnosis and treatment of mucopolysaccharidosis I (MPS I) have changed over time. We used data from 891 patients in the MPS I Registry, an international observational database, to analyze ages at symptom onset, diagnosis, treatment initiation, and treatment allocation (hematopoietic stem cell transplantation, enzyme replacement therapy with laronidase, both, or neither) over time for all disease phenotypes (Hurler, Hurler–Scheie, and Scheie syndromes). The interval between diagnosis and treatment has become shorter since laronidase became available in 2003 (gap during 2006–2009: Hurler—0.2 year, Hurler–Scheie—0.5 year, Scheie—1.4 years). However, the age at diagnosis has not decreased for any MPS I phenotype over time, and the interval between symptom onset and treatment initiation remains substantial for both Hurler–Scheie and Scheie patients (gap during 2006–2009, 2.42 and 6.71 years, respectively). Among transplanted patients, an increasing proportion received hematopoietic stem cells from cord blood (34 out of 64 patients by 2009) and was also treated with laronidase (42 out of 45 patients by 2009). Conclusions: Despite the availability of laronidase since 2003, the diagnosis of MPS I is still substantially delayed for patients with Hurler–Scheie and Scheie phenotypes, which can lead to a sub-optimal treatment outcome. Increased awareness of MPS I signs and symptoms by primary care providers and pediatric subspecialists is crucial to initiate early treatment and to improve the quality of life of MPS I patients.
Published Version: doi:10.1007/s00431-011-1644-x
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3357468/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:10385393
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)


Search DASH

Advanced Search